Trump Administration Changes the Classification of Medical Cannabis Products

What Happened?

The Trump Administration announced on Thursday it is changing the classification of cannabis products that are Food and Drug Administration (FDA) approved or have a state license. For cannabis containing products with FDA approval or state licensure, the classification will change from schedule one to schedule three. 

Acting U.S. Attorney General Todd Blanche said, ‘This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care.’ The Department of Justice has begun expediting the hearing process to more broadly reclassify marijuana under federal law, and the Drug Enforcement Administration will hold an administrative hearing on the issue June 29^th. 

Why it Matters

Forty-five states in the U.S. have legalized cannabis in some form, with most of those allowing the use of medical cannabis and several more authorizing recreational use. Federal guidelines have remained more stringent, but the move by the Trump Administration will change cannabis from schedule one, which is the most restricted and highly regulated category of drugs, to category three, which is the same level used for over-the-counter medications such as aspirin. The change will likely make cannabis more accessible for millions of Americans.

My accountant called me an idiot

When I told my accountant I put money into a $0.50 stock, he literally laughed.

"What is this, a penny stock?"

No.

It's a company with $115 million in revenue. $11.8 million in EBITDA. Profitable since April 2025. 490 million users. Ranked #1 fastest growing by Deloitte. Backed by Kevin Harrington , and sitting on a reserved Nasdaq ticker.

I sent him one link.

He called me back in 40 minutes.

"How much can I put in?"

That's the thing about this deal. Every objection dies on arrival.

"Too cheap" — it's pre-IPO, that's the whole point. "Never heard of it" — neither had anyone who bought Amazon at $18. "Sounds too good" — then read the Deloitte report yourself.

$0.50/share. Up to 20% bonus. 59,000 investors already in.*

My accountant isn't laughing anymore.

See what shut him up.

Though cannabis isn't legal at the federal level under schedule one, the new change will make it easier for the industry to operate and for research to be carried out. Sixty-four percent of Americans supported legalization in a Gallop survey from 2025, up from thirty-six percent in 2000. The move by the Trump Administration likely reflects the change in public opinion and the fact that most Americans now believe cannabis should be legal for them to purchase and use.

Veterans’ advocacy groups have long called for the legalization of cannabis because of its fast-acting effects. If a veteran is suicidal and takes medication to calm down, conventional medication could take too long to kick in, whereas inhaling cannabis produces an immediate effect that could prevent someone from taking their own life.

While critics used to call cannabis a gateway drug, meaning using it can lead to using other, more dangerous substances, most advocates now refer to cannabis as an exit drug, because by taking it, people can stop using other harder medications. 

Despite the schedule change for cannabis by the Trump Administration, the move is still short of full legalization at the federal level. That would require Congress to pass federal legislation making cannabis legal, and though several attempts at such passage have been made, none have succeeded.

How it Affects You

The new schedule change will take effect in thirty days, and during that time, the change can be challenged in court. Court challenges to cannabis laws have been levied in the past, but because this is an administrative ruling, not a law, it will be harder to get a court order to stop it. Federal lawmakers may now be more inclined to support legalization since cannabis will no longer be a schedule one drug.

*Disclaimer: Please read the offering circular and related risks at invest.modemobile.com. This is a paid advertisement for Mode Mobile’s Regulation A+ Offering.

Mode Mobile recently received their ticker reservation with Nasdaq ($MODE), indicating an intent to IPO in the next 24 months. An intent to IPO is no guarantee that an actual IPO will occur.

The Deloitte rankings are based on submitted applications and public company database research, with winners selected based on their fiscal-year revenue growth percentage over a three-year period.

Pro forma revenue and EBITDA, includes full year numbers of the businesses acquired throughout 2025.

Mode cumulative revenue includes full year revenue of businesses acquired in 2025.